A comparative evaluation of mikrolatest kit broth microdilution and VITEK2 in assessing colistin susceptibility to Gram-negative bacterial isolates


  • Reddy B. Rama Chandra
  • PAT Jagatheeswary
  • Singh Manisha
  • Reddy Y. Raja Ratna
  • K. Sreeja Vamsi
  • Nissi Priya




Gram-negative bacilli, colistin resistance, Mikrolatest, broth micro-dilution method


Introduction and Aim: The increasing resistance in colistin is a major concern. The aim of the study was to compare the methods to identify the prevalence of colistin resistance and antibiotic susceptibility patterns of colistin resistant strains isolates from blood, urine and sputum samples at all ICUs including NICU and PICU and wards.


Materials and Methods: A total of 1458 consecutive Gram-negative isolates were tested for colistin susceptibility by standard broth microdilution method, Mikrolatest method and VITEK 2 automation system. Intrinsically colistin resistant organisms including Proteus sps, Providencia sps, Serratia sps., and Morganella morganii were excluded. Enterobacteriaceae (e.g., Escherichia coli, Klebsiella), Pseudomonas   aeruginosa and Acinetobacter baumanii were included. The sensitivity, specificity, positive predictive value, negative predictive value of Vitek-2, BMD and Mikrolatest methods were compared. 


Results: Sixteen (1.09%) colistin?resistant isolates were reported over 24 months. K. pneumoniae constituted 8(50%), E. coli 6 (37.5%) and Enterobacter cloacae 2 (12.5%) of the 16 resistant isolates. The sensitivity, specificity, positive predictive value, negative predictive value of Mikrolatest compared with that of VITEK2 were 87.5% vs 56.25%, 90.84% vs 82.65%, 9.58% vs 3.47%and 99.8% vs 99.3%, respectively for resistant isolates.  Mikrolatest shared good Category agreement of 1.24% with BMD Essential agreement was 1.5%. Comparing MICs of BMD with other tests, essential agreement was the lowest for the VITEK2, while the Mikrolatest MIC showed essential agreement greater than 1.5%. No errors and 100% categorical agreement (for E. coli, K. pneumoniae) were observed while comparing colistin susceptibility test results of the Mikrolatest MIC and BMD tests. The difference between the two methods in assessing colistin resistance were not statistically significant (P=0.89). Blood[37.5%] and pus[37.5%] samples recorded as the common sources of the isolate, followed by Urine [12.5%], and respiratory [12.5%) samples.


Conclusion: Automated VITEK, Mikrolatest MIC methods give variable susceptibility results and colistin should be prescribed only after Mikrolatest and BMD. K. pneumoniae and E. coli, the Mikrolatest showed better performance for isolates with ? 0.5 or ? 16 µg/mL MICs. For P. aeruginosa isolates, colistin resistant isolates must be confirmed Colistin resistance among Gram-negative bacteria, especially K. pneumoniae, is emerging in Indian hospitals. Re-evaluation is required of the methods available to address the numerous technical challenges associated with colistin susceptibility testing, and to determine which method yields the most meaningful results. These studies will provide critical information on the appropriate selection of colistin therapy, as well as evaluating novel and upcoming compounds with structure and properties similar to the Polymyxin.

Author Biographies

Reddy B. Rama Chandra

Department of Microbiology, S.V.S Medical College, Mahaboobnagar, Telangana, India

PAT Jagatheeswary

Department of Microbiology, Saveetha Medical College, Saveetha University, Chennai, Tamil Nadu, India

Singh Manisha

Department of Microbiology, Vijaya Diagnostic Centre, Himayathnagar, Hyderabad, Telangana, India

Reddy Y. Raja Ratna

Department of Microbiology, S.V.S Medical College, Mahaboobnagar, Telangana, India

K. Sreeja Vamsi

Department of Microbiology, S.V.S Medical College, Mahaboobnagar, Telangana, India

Nissi Priya

Department of Microbiology, S.V.S Medical College, Mahaboobnagar, Telangana, India


Sader, H. S., Farrell, D. J., Flamm, R., Jones, R. N. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Micr Infec Dis. 2014; 78(4): 443-448.

Tan, R., Liu, J., Li, M., Huang, J., Sun, J., Qu, H. Epidemiology and antimicrobial resistance among commonly encountered bacteria associated with infections and colonization in intensive care units in a university- affiliated hospital in Shanghai. J Microbiol Immunol. 2014; 47(2): 87-94.

Eliopoulos, G. M., Cosgrove, S. E., Carmeli, Y.The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis, 2003; 36(11): 1433-1437.

Lam, S. J., O'Brien-Simpson, N. M., Pantarat, N., Sulistio, A., Wong, E. H., Chen, Y. Y., et al., Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers. Nat. Microbiol. 2016; 1(11): 1-11.

Xu, Y., Gu, B., Huang, M., Liu, H., Xu, T., Xia, W., et al., Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000- 2012 in Asia. J Thorac Dis. 2015; 7(3): 376-385.

Perez, F., Van Duin, D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med, 2013; 80(4): 225-233.

Cantón, R., Akóva, M., Carmeli, Y., Giske, C. G., Glupczynski, Y., Gniadkowski, M., et al., Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect, 2012; 18(5): 413-431.

Livermore, D. M. Has the era of untreatable infections arrived? J Antimicrob Chemother, 2009;64(suppl_1): i29-i36.

Falagas, M. E., Kasiakou, S. K., Saravolatz, L. D. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40(9): 1333-1341.

Yahav, D., Farbman, L., Leibovici, L., Paul, M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infec. 2012; 18(1): 18-29.

Nation, R. L., Li, J. Colistin in the 21st century. Curr Opin Infect Dis. 2009; 22(6): p. 535.

Walkty, A., DeCorby, M., Nichol, K., Karlowsky, J. A., Hoban, D. J., Zhanel, G. G. In vitro activity of colistin (polymyxin E) against 3,480 isolates of Gram- negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007- 2008. Antimicrob Agents Chemother. 2009; 53(11): 4924-4926.

Patel, J. B., Cockerill, F. R., Bradford, P. A. Performance standards for antimicrobial susceptibility testing: twenty-fifth informational supplement. 2015. Clinical and Laboratory Standards Institute. 2015; 35(3): 29-50.

Lee, M., Chung, H. S. Different antimicrobial susceptibility testing methods to detect ertapenem resistance in Enterobacteriaceae: VITEK2, MicroScan, Etest, disk diffusion, and broth microdilution. J. Microbiol. Methods. 2015; 112: 87-91.

Juyal, D., Thawani, V., Thaledi, S., Dhawan, B. Polymyxin Nordmann/Poirel test for rapid detection of polymyxin resistance in Enterobacteriaceae: Indian experience. Indian J. Med. Microbiol. 2016; 34(4): 564.

Lai, C. C., Chen, Y. S., Lee, N. Y., Tang, H. J., Lee, S. S. J., Lin, C. F., et al., Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: Results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). Infect Drug Resist. 2019; 12: 627.

Singh, R. I., Bhatia, M., Anusha, K. R., Singh, V., Omar, B. J., Gupta, P. Comparative evaluation of microscan walkaway 96 plus ID/AST system and mikrolatest broth microdilution kit in assessing In vitro colistin susceptibility of carbapenem-resistant clinical gram-negative bacterial isolates: Experience from a tertiary care teaching hospital in Rishikesh, Uttarakhand. Indian J. Med. Microbiol. 2019; 37(4): 502.

Falagas, M. E., Rafailidis, P.I., Matthaiou, D.K. Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Update. 2010. 13(4-5): 132-138.

Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., et al., Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2006; 50(9): 2946-2950.

Hawley, J. S., Murray, C. K., Jorgensen, J. H. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. A Antimicrob. Agents Chemother. 2008; 52(1): 351-352.

Schäfer, E., Malecki, M., Tellez - Castillo, C. J., Pfennigwerth, N., Marlinghaus, L., Higgins, P. G., et al., Molecular surveillance of carbapenemase-producing Pseudomonas aeruginosa at three medical centres in Cologne, Germany. Antimicrob Resist In. 2019; 8(1): 1-7.

Jayol, A., Nordmann, P., André, C., Poirel, L., Dubois, V. Evaluation of three broth microdilution systems to determine colistin susceptibility of Gram-negative bacilli. J Antimicrob Chemother. 2018; 73(5): 1272-1278.

Pfennigwerth, N., Kaminski, A., Korte-Berwanger, M., Pfeifer, Y., Simon, M., Werner, G., et al., Evaluation of six commercial products for colistin susceptibility testing in Enterobacterales. Clin Micro Inf. 2019. 25(11): 1385-1389.

Garcia, L. S. ed., Clinical microbiology procedures handbook. American Society for Microbiology Press. 2010: 2.




How to Cite

B. Rama Chandra R, Jagatheeswary P, Manisha S, Y. Raja Ratna R, Sreeja Vamsi K, Priya N. A comparative evaluation of mikrolatest kit broth microdilution and VITEK2 in assessing colistin susceptibility to Gram-negative bacterial isolates. Biomedicine [Internet]. 2021Jul.7 [cited 2021Jul.24];41(2):260-7. Available from: https://biomedicineonline.org/index.php/home/article/view/793



Original Research Articles